Syndax Pharmaceuticals shares are trading lower after the FDA extended the review period for the company's leukemia drug Revumenib.
Portfolio Pulse from Benzinga Newsdesk
Syndax Pharmaceuticals shares are trading lower after the FDA extended the review period for the company's leukemia drug Revumenib.
July 29, 2024 | 2:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Syndax Pharmaceuticals shares are trading lower due to the FDA extending the review period for their leukemia drug Revumenib.
The extension of the FDA review period introduces uncertainty and potential delays in the approval process for Revumenib, negatively impacting investor sentiment and causing the stock price to drop.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100